Sermorelin

What it is

Sermorelin (sermorelin acetate) is a synthetic 29-amino-acid peptide identical to the first 29 amino acids of native human growth hormone-releasing hormone (GHRH). The first 29 residues of the 44-amino-acid native GHRH contain essentially all of the biological activity, making this truncated version pharmacologically equivalent to full-length GHRH.

Sermorelin was originally developed and FDA-approved (as Geref) in 1990 for the diagnostic evaluation of growth hormone deficiency in pediatric patients. Commercial production was later discontinued for business reasons unrelated to safety or efficacy. The molecule remained available through licensed compounding pharmacies and has been widely used off-label in adult endocrinology and longevity medicine for decades.

Of all the growth hormone secretagogues we prescribe, sermorelin has the longest clinical track record and the most robust safety database. Its mechanism — stimulating endogenous, pulsatile GH release through native pathways — represents what we consider the safest approach to GH-axis support in adults with documented age-related decline.

Mechanism of action

Sermorelin binds the GHRH receptor on pituitary somatotrophs (the cells that produce growth hormone), stimulating GH synthesis and pulsatile release. Critically, this action preserves several physiologic safeguards that are absent when exogenous recombinant GH is administered directly:

• Pulsatile release: the body releases GH in pulses (typically 4–6 per 24 hours, with the largest pulse during early sleep). Sermorelin enhances the amplitude of natural pulses without producing continuous supraphysiologic GH levels.
• Negative feedback intact: elevated IGF-1 and somatostatin signaling can still modulate GH release in response to sermorelin, preventing excessive GH elevation.
• Pituitary regulation: the pituitary acts as a release rate-limiter, preventing GH levels from climbing to the ranges associated with acromegaly that exogenous GH can produce if dosed inappropriately.

The half-life of sermorelin is short (~10–20 minutes), which is consistent with its role as a pulsatile signal rather than a sustained-action drug. This pharmacokinetic profile is the basis for nightly dosing — administering sermorelin before sleep amplifies the largest natural GH pulse without creating non-physiologic patterns.

Research findings

Diagnostic utility: sermorelin’s original FDA approval rested on robust evidence that it could distinguish hypothalamic GH deficiency (intact pituitary response) from pituitary GH deficiency (no response).

Pediatric GH deficiency treatment: trials in the 1990s and 2000s demonstrated efficacy in supporting linear growth in children with GH deficiency, with growth velocity improvements of 1.5–2x baseline.

Adult studies: smaller body of literature in adults. Studies have demonstrated:

• Restoration of more youthful GH and IGF-1 levels in adults with documented age-related GH axis decline
• Improvements in body composition (modest decreases in fat mass, modest increases in lean mass) over 12–24 week cycles
• Improvements in sleep quality and subjective well-being
• Possible improvements in skin quality, exercise capacity, and recovery from training

Effect sizes in adult studies are smaller than those seen with direct recombinant GH but with substantially better safety profile and lower cost. Sermorelin’s adult use has been extensively documented in clinical practice but has not had the large randomized trials needed for new FDA indications.

How we use it at The Tide

Sermorelin is prescribed for adults with documented age-related GH axis decline who have specific clinical concerns and have completed appropriate workup. We do not prescribe sermorelin (or any GH secretagogue) for vague longevity goals without supporting clinical context.

Appropriate candidates typically have:

• IGF-1 levels in the lower quartile for age, indicating reduced GH axis activity
• Specific complaints amenable to GH support: declining body composition despite stable diet and exercise, poor sleep depth, slower recovery from training, declining exercise capacity
• Completed baseline workup including IGF-1, fasting glucose and HbA1c, comprehensive metabolic panel, lipid panel, and screening for malignancy concerns
• Absence of contraindications

Standard dosing: 200–400 mcg subcutaneously at bedtime, 5 nights per week, for 12-week cycles. We frequently combine sermorelin with ipamorelin (or alternatively prescribe CJC-1295 + ipamorelin) to capture the synergistic GH release from combined GHRH and GHRP signaling.

Monitoring: repeat IGF-1 at 90 days. Target is to bring IGF-1 into the upper third of the age-appropriate reference range without exceeding it. We also follow weight, body composition, fasting glucose, and patient-reported outcomes.

Cycling: 12 weeks on, 4–6 weeks off is our typical pattern. Continuous use is not recommended.

Side effects and contraindications

Sermorelin is well-tolerated at clinical doses. Possible side effects:

• Transient flushing or warmth at injection time, typically resolving within minutes
• Mild headache, particularly in the first week
• Injection site irritation
• Joint discomfort or fluid retention if dosing is excessive — these are signs to reduce the dose
• Tingling or numbness in extremities (carpal tunnel-like symptoms) at higher doses
• Vivid or unusual dreams, particularly when first starting

Contraindicated in:

• Active malignancy (any GH-axis stimulant is contraindicated due to GH/IGF-1’s growth-promoting effects)
• Uncontrolled diabetes (GH can worsen insulin resistance)
• Severe obesity (which suppresses GH response and is associated with elevated cardiovascular risk that should not be compounded)
• Pregnancy and breastfeeding
• Known pituitary disease
• Active diabetic retinopathy

What we don’t yet know

Long-term outcomes of multi-year cyclical sermorelin use in adults are not well characterized in formal studies, though decades of clinical experience suggest favorable safety. The optimal IGF-1 target range for adults seeking GH support — high-normal vs. mid-normal — is debated. Effects on hard outcomes like cardiovascular disease, cognitive trajectory, and longevity itself are not established. The relative merits of sermorelin vs. CJC-1295 (no DAC) — a longer-acting GHRH analog — are largely a matter of individual patient response and clinician preference rather than head-to-head evidence. We present sermorelin to patients as a well-established tool for supporting GH axis function in appropriate candidates, with realistic expectations about effect sizes and the importance of sustainable lifestyle factors as the foundation of any health goal.